Tony Berberabe, MPH | Authors


Twice Daily Poziotinib Beats Safety of Single Dose in NSCLC

April 05, 2021

Perliminary analyses of 2 cohorts from the phase 2 multicohort ZENITH20 trial evaluating poziotinib show clinical activity and tolerability for the tyrosine kinase inhibitor in patients with non–small cell lung cancer harboring EGFR and HER2 exon 20 insertions.

Expanding Molecular Testing Leads to Personalized Care in GI Cancer

March 29, 2021

A key advance in treating patients with gastrointestinal cancer is molecular profiling of the tumor that results in specific targets being identified. The standard of care for GI cancer has consisted of surgery, radiotherapy, and chemotherapy, but these standards have had limited efficacy and considerable toxicity that impact patients’ quality of life.